Errata

Erratum

In the article by Susana Almeida, Augusto Filipe, Rita Neves, Isabelle Desjardins, Eric Shink, and Araceli Castillo “Bioequivalence study of two different tablet formulations of donepezil using truncated areas under the curve/A single-center, single-dose, randomized, openlabel, 2-way crossover study under fasting conditions”, published in Arzneimittelforschung 2010;60(3):116–123, [Table 4] contains wrong data. The correct table is shown below.

Table 4: MedDRA, version 11.1, characterization of the post-dose adverse events experienced by subjects.

System Organ Class MedDRA Preferred Term	Treatment group
		Test	Reference
Number of subjects dosed	19	18
Gastrointestinal disorders		2 (11.1%)
Abdominal pain		1 (5.6%)
Nausea		1 (5.6 %)
Infections and infestations		1 (5.6%)
Nasopharyngitis		1 (5.6%)
Injury, poisoning and procedural	3 (15.8%)	2 (11.1%)
complications
Post procedural haematoma		1 (5.6 %)
Post procedural swelling	3 (15.8%)	1 (5.6 %)
Procedural pain	1 (5.3%)	1 (5.6%)
Investigations	2 (10.5%)	2 (11.1%)
Alanine aminotransferase increased	1 (5.3%)
Blood pressure decreased		1 (5.6 %)
Blood pressure increased	1 (5.3%)
Heart rate decreased		1 (5.6 %)
White blood cells urine positive	1 (5.3%)
Musculoskeletal and connective tissue	1 (5.3%)	1 (5.6%)
disorders
Muscle spasms		1 (5.6 %)
Muscular weakness	1 (5.3%)
Myalgia		1 (5.6%)
Nervous system disorders	2 (10.5%)	2 (11.1%)
Dizziness		1 (5.6%)
Headache	2 (10.5%)
Somnolence		1 (5.6 %)
Reproductive system and breast		1 (5.6%)
disorders
Dysmenorrhoea		1 (5.6 %)
Skin and subcutaneous tissue disorders	1 (5.3%)
Skin irritation	1 (5.3%)
Total subjects who experienced adverse	6 (31.6%)	7 (38.9%)
events